Literature DB >> 11744132

Pharmacological stress agents for evaluation of ischemic heart disease.

J Ali Raza1, W C Reeves, A Movahed.   

Abstract

Ischemic heart disease is the leading cause of death in the developed countries for those older than 65 years of age. In patients suspected to have coronary artery disease a stress test should be performed to identify the vulnerability of the myocardium to ischemia. As a rule of thumb, the evaluation of coronary artery disease is best done by exercise stress test. In patients who are not able to exercise adequately, pharmacological stress agents are used. The commonly used agents are the coronary vasodilators, adenosine and dipyridamole and the catecholamines, dobutamine and arbutamine. These agents are combined with imaging techniques to increase the sensitivity and specificity of the test. These agents have been widely used and have an excellent safety profile. Another advantage in using pharmacological stress agents is that they do not affect the image quality, especially with echocardiography and magnetic resonance imaging. Ongoing developments hold promise for safer and more reliable pharmacological stress agents in the future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11744132     DOI: 10.1016/s0167-5273(01)00536-8

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  The adverse events and hemodynamic effects of adenosine-based cardiac MRI.

Authors:  Thomas Voigtländer; Axel Schmermund; Peter Bramlage; Amelie Elsässer; Annett Magedanz; Hans-Ulrich Kauczor; Oliver K Mohrs
Journal:  Korean J Radiol       Date:  2011-07-22       Impact factor: 3.500

2.  Head-to-head comparison of first-pass MR perfusion imaging during adenosine and high-dose dobutamine/atropine stress.

Authors:  Robert Manka; Cosima Jahnke; Rolf Gebker; Bernhard Schnackenburg; Ingo Paetsch
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-19       Impact factor: 2.357

3.  Myocardial strain indices and coronary flow reserve are only mildly affected in healthy hypertensive patients.

Authors:  Dimitrios Evangelou; Aris Bechlioulis; Georgios Tzeltzes; Lampros Lakkas; Ioanna Theodorou; Rigas Kalaitzidis; Evangelia Dounousi; Lampros K Michalis; Katerina K Naka
Journal:  Int J Cardiovasc Imaging       Date:  2020-07-30       Impact factor: 2.357

4.  The quantification of dipyridamole induced changes in regional deformation in normal, stunned or infarcted myocardium as measured by strain and strain rate: an experimental study.

Authors:  Maciej Marciniak; Piet Claus; Witold Streb; Anna Marciniak; Petra Boettler; Myles McLaughlin; Jan D'hooge; Frank Rademakers; Bart Bijnens; George R Sutherland
Journal:  Int J Cardiovasc Imaging       Date:  2007-10-02       Impact factor: 2.357

5.  Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin.

Authors:  Yumei Ye; Bo Long; Jinqiao Qian; Jose R Perez-Polo; Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2010-12       Impact factor: 3.727

6.  Characterization of the Human Coronary Microvascular Response to Multiple Hyperaemic Agents.

Authors:  Massimo Nardone; Mary McCarthy; Chris I Ardern; Heather Edgell; Olga Toleva; Lynne E Nield; Steven E S Miner
Journal:  CJC Open       Date:  2020-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.